Why Novartis (NVS) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
JD Supra1d
Investigations Newsletter: Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims
Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims - Last week, the Second Circuit Court of Appeals affirmed ...
The Financial Express12h
Novartis gene therapy poised to expand SMA treatment landscape
Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...
FiercePharma5d
After delay with FDA, Novartis touts pivotal trial win for intrathecal Zolgensma in older SMA patients
More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...
Novartis Says New Drug Helps Children With Rare Spinal Condition
Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the ...
Berenberg Bank Sticks to Its Hold Rating for Novartis AG (NOVN)
Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)
Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
pharmaphorum7d
New data could widen use of Novartis' SMA therapy Zolgensma
Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...
Pharmaceutical Technology2d
Iptacopan hydrochloride by Novartis for Proteinuria: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Positive data could expand use of Novartis’ gene therapy for SMA
On 30 December 2024, Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached ...
Novartis8d
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...